



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2011

---

**Response to Comment on: Lin et al. (2010) Immune Cell–Derived C3 Is  
Required for Autoimmune Diabetes Induced by Multiple Low Doses of  
Streptozotocin. Diabetes;59:2247–2252**

Seegerer, S

DOI: <https://doi.org/10.2337/db10-0044>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-43118>

Journal Article

Accepted Version

Originally published at:

Seegerer, S (2011). Response to Comment on: Lin et al. (2010) Immune Cell–Derived C3 Is Required for Autoimmune Diabetes Induced by Multiple Low Doses of Streptozotocin. Diabetes;59:2247–2252. Diabetes, 59:2247–2248.

DOI: <https://doi.org/10.2337/db10-0044>

## Immune Cell Derived C3 is Required for Autoimmune Diabetes Induced by Multiple Low Doses of Streptozotocin

Running title: Complement and Autoimmune Diabetes

Marvin Lin<sup>1</sup>, Na Yin<sup>2</sup>, Barbara Murphy<sup>1,3</sup>, M. Edward Medof<sup>4</sup>, Stephan Segerer<sup>5</sup>, Peter S. Heeger<sup>1,3,6</sup>, Bernd Schröppel<sup>1,3,6</sup>

<sup>1</sup>Division of Nephrology; <sup>2</sup>Department of Gene and Cell Medicine; <sup>3</sup>Transplantation Institute, Mount Sinai School of Medicine, New York, NY, USA; <sup>4</sup>Institute of Pathology, Case Western Reserve University, Cleveland, OH USA; <sup>5</sup>Division of Nephrology, University Hospital Zurich, Zurich, Switzerland  
<sup>6</sup>Co-senior authors

### Address correspondence to:

Dr. Bernd Schröppel

E-mail: [bernd.schroppel@mountsinai.org](mailto:bernd.schroppel@mountsinai.org)

Additional information for this article can be found in an online appendix at <http://diabetes.diabetesjournals.org>

Submitted 12 January 2010 and accepted 21 June 2010.

This is an uncopyedited electronic version of an article accepted for publication in *Diabetes*. The American Diabetes Association, publisher of *Diabetes*, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of *Diabetes* in print and online at <http://diabetes.diabetesjournals.org>.

*Objective:* The complement system contributes to autoimmune injury, but its involvement in promoting development of autoimmune diabetes is unknown. This study was aimed to ascertain the role of complement C3 in autoimmune diabetes.

*Research Design and Methods:* Susceptibility to diabetes development after multiple low dose streptozotocin treatment in wild-type (WT) and C3 deficient mice was analyzed. Bone marrow chimeras, luminex, and qRT-PCR assays were performed to evaluate the phenotypic and immunological impact of C3 in the development of this model of diabetes.

*Results:* Coincident with the induced elevations in blood glucose levels, we documented alternative pathway complement component gene expression within the islets of the diabetic WT animals. When we repeated the experiments with C3 deficient mice we observed complete resistance to disease, as assessed by the absence of histological insulitis and the absence of T cell reactivity to islet antigens. Studies of WT chimeras bearing C3 deficient bone marrow cells showed that bone marrow cell-derived C3 and not serum C3 is involved in the induction of diabetes in this model.

*Conclusions:* The data reveal a key role for immune cell derived C3 in the pathogenesis of murine multiple low dose streptozotocin induced diabetes and support the concept that immune cell mediated diabetes is in part complement-dependent.

Type 1 diabetes mellitus is a T cell dependent autoimmune disease in which islet antigens are presented by antigen presenting cells (APCs) to autoreactive T cells, breaking self tolerance (1,2). Following attraction to the pancreas, the autoreactive CD4 T cells cause beta cell injury in part through secreting proinflammatory cytokines that directly act on the islet cells (3) as well as by activating macrophages that amplify injury (4).

In previous work we showed that during cognate T cell/APC interactions immune cell-derived complement activates locally, yielding C3a and C5a that bind to C3a/C5a receptors (C3aR/C5aR) on both partners (5). The resultant G-protein coupled receptor (GPCR) signaling further activates the APCs (upregulating costimulatory molecule expression and innate cytokine production) and directly induces survival and proliferation of the responding T cells. These concepts apply to in vivo immunity as T cell

responses to autoantigens (6-8), transplant antigens (9-12), and viruses (5,13) are diminished in mice in which immune cells are deficient in C3 or C3aR/C5aR, while T cell immunity is enhanced in mice in which immune cells are deficient in the cell surface complement regulatory protein decay-accelerating factor (DAF, CD55) (8,10).

These results along with a multitude of reports documenting that complement contributes to autoimmune injury (14-16) prompt the question of the possible involvement of the complement effectors in promoting the development of T cell mediated diabetes. This gap in the understanding of the function of complement in type 1 diabetes is unexpected, given that complement effectors, in particular C3a and C5a, are potent proinflammatory mediators and that inflammation has long been linked in the pathogenesis of type 1 diabetes.

To test the role of complement C3 on the development of T cell mediated diabetes,

we employed an established model using multiple low dose streptozotocin treatment. We chose the MLDS model over the NOD model because C3 and the diabetes susceptibility genes in the NOD strain are closely linked on chromosome 17 (17,18), thus impairing our ability to produce C3 deficient NOD animals. Streptozotocin (STZ), a toxin that binds to the GLUT2 receptor on pancreatic beta cells, has been used for decades to induce diabetes in rodent models (19). When administered at a single high dose (Hi-STZ, 180 mg/kg), it induces necrosis of the beta cells without leukocytic infiltrate. Collapsed islets and elevated serum glucose levels are detectable within 2-3 days (20). In contrast, when STZ is administered as multiple low-doses (MLDS, 40 mg/kg/day for 5 days), it induces distortion of the islet architecture in conjunction with mononuclear cell infiltration. While elevated serum glucose can be detected as early as day 7, 2-3 weeks are typically required for sustained diabetes (19). Rather than necrosis, apoptosis is the underlying mechanism of islet cell death, documented by findings that animals deficient in islet-associated caspase-3 are resistant to STZ effects (21). Current concepts are that the apoptosis provides an environment in which islet autoantigens can be processed and presented by infiltrating APCs. Immune cell mediated injury by autoreactive T cells that have escaped thymic deletion is the dominant pathogenic mechanism (22). Consistent with this hypothesis, studies in the early 1980s demonstrated that T cell depleted or deficient (nude) animals are resistant to MLDS-induced diabetes (23-25) and that T cells from animals with MLDS-induced disease can transfer diabetes to naïve mice (26,27).

Herein we report that immune cell C3 is required for MLDS induced diabetes and strikingly, that the C3 must derive from immune cells rather than from the serum. Our

results suggest that further studies are warranted in autoimmune diabetes in humans.

## RESEARCH DESIGN AND METHODS

**Reagents and Antibodies.** Anti-mouse CD45.1-PE, CD45.2-PerCP-Cy5.5, anti-mouse IFN- $\gamma$  and biotinylated anti-IFN- $\gamma$  mAb, anti-Annexin V-PE (BD Biosciences; San Jose, CA); anti-mouse C3-FITC (MP Biomedicals; Solon, OH); alkaline phosphatase-conjugated anti-biotin antibody (Vector Laboratories; Burlingame, CA); streptavidin-HRP conjugate (Dako; Carpinteria, CA); collagenase P (Roche; Mannheim, Germany); zymosan A (Sigma Aldrich; St. Louis, MO); streptozotocin (Alexis Biochemicals; Farmingdale, NY).

**Mice.** BALB/cJ (H-2<sup>d</sup>), C57BL/6 (H-2<sup>b</sup>), B6.SJL-Ptprc<sup>a</sup> Pepc<sup>b</sup>/BoyJ (CD45.1), B6.C3<sup>-/-</sup>, and RAG-1<sup>-/-</sup> (B6.129S7-Rag1<sup>tm1Mom/J</sup>), nude (B6.Cg-Foxn1<sup>nu</sup>/J) male mice were purchased from The Jackson Laboratory (Bar Harbor, ME). B6.C3<sup>-/-</sup> mice were backcrossed (>10 generations) to BALB/c to obtain BALB/c.C3<sup>-/-</sup>. C3 deficiency was confirmed via zymosan A C3 binding assay (11). Male mice were used at ages of 6 to 10 weeks of age, housed under specific-pathogen-free conditions, and treated in strict compliance with regulations established by the Institutional Animal Care and Use Committee.

**Diabetic model, islet isolation and islet transplantation.** To induce diabetes, male mice (6–10 wk of age) were injected i.p. for 5 consecutive days with streptozotocin (40 mg/kg) dissolved in cold 0.1 M citrate buffer pH 4.5 as previously described (26). Tail-vein glucose was measured between 10 AM and 12 PM and mice were considered diabetic when blood glucose levels were >200 mg/dL in two consecutive measurements on the OneTouch Ultra Blood Glucose Meter (LifeScan Inc; Milpitas, CA). In some experiments mice were treated with a single 180 mg/kg body weight i.p. injection of STZ. Islet isolation

and transplantation were previously described (28). Isolated islets from male B6 mice were cultured overnight and incubated with STZ (0.5 mg/ml) for 1 hour, washed, and transplanted beneath the renal capsule of diabetic male B6 recipients (29). Islets were transplanted 10 days after initiating MLDS or 5 days after Hi-STZ treatment in the recipient mice. Intraperitoneal glucose tolerance testing was performed on day 7 after transplantation and the area under the curve (AUC) was calculated.

**Generation of bone marrow (BM) chimeric mice.** BM cells were collected from male WT or C3<sup>-/-</sup> mice of B6 background. Recipient male B6 mice had been lethally irradiated with 900 rads (2 doses of 450 rads with 3 hr resting period) from a cesium source using a Mark I Model 137Cs irradiator (JL Shepherd & Associates; An Fenrando, CA). Six hours after irradiation, recipient irradiated mice received  $8 \times 10^6$  BM cells via the tail vein. Chimerism of >90% donor origin was confirmed at week 8 by staining for CD45.1 vs. CD45.2 and systemic C3 was assayed by flow cytometry via zymosan binding followed by staining (11).

**Adoptive Cell Transfer.** Splenocytes from male WT or C3<sup>-/-</sup> mice of B6 background were obtained by gently grinding moistened spleen through a 70- $\mu$ m filter and washed. Red blood cells were lysed with ACK Lysis Buffer (Invitrogen; Carlsbad, CA). Splenocytes were resuspended in sterile PBS at a concentration of  $3 \times 10^6$  /200 $\mu$ l for intraperitoneal transfer into male B6.C3<sup>-/-</sup> mice. Twenty-four hours after adoptive transfer, recipient B6.C3<sup>-/-</sup> mice were treated with MLDS.

**Annexin V Staining.** Isolated islets were cultured overnight with STZ (0.5mg/ml) at 37°C in humidified air and 5% CO<sub>2</sub>. Islets were disrupted into a single-cell suspension and Annexin V staining and analysis was performed as manufacturer instructed.

**Flow Cytometry.** All flow cytometry experiments were performed using a BD FACSCanto II (BD Biosciences; San Jose, CA) and data were analyzed on FlowJo software (TreeStar Inc; Ashland, OR).

**Quantitative RT-PCR.** Total RNA was extracted from the distal portion of the pancreas devoid of lymphoid tissue using TriZol solution (Life Technologies; Carlsbad, CA) and cDNA was generated with oligo(dT) primers. PCR was performed on a CFX96 Real Time System (Bio-Rad; Hercules, CA) with the FastStart QuantiTect SYBR Green PCR kit (Qiagen; Valencia, CA) as described (28). Quantitative RT-PCR data was normalized to cyclophilin. Primer sequences are available upon request.

**Histopathology and Insulitis Evaluation.** Islet grafts were harvested and fixed in OCT compound. Frozen sections were cut into 5  $\mu$ m thick sections and islet morphology and leukocyte infiltration were assessed by H&E-staining. Islets were graded by a blinded investigators for severity of insulitis from a scale of 0-4: islets devoid of mononuclear cells =0; minimum focal islet infiltrate = 1+; peri-islet infiltrate of <25% of islet circumference = 2+; peri-islet infiltration and <50% intra-islet infiltrate = 3+; intra-islet infiltration >50% of islet area = 4+. The insulitis score (%) for each group was calculated as: Sum of (1x number of islets with 1+, 2x number of islets with 2+, 3x number of islets with 3+, 4x number of islets with 4+) divided by 4x total number of islets scored (30). The calculated ratio represents the insulitis score percentage and was expressed as the mean $\pm$ SEM. Each study group included three mice with a minimum of 10 islets scored.

**Luminex Assay.** Splenocytes were harvested on experimental day 0, 10, or 19 from MLDS treated male B6 and B6.C3<sup>-/-</sup> mice. Dilutions of spleen cells were plated in HL-1 media stimulated in the presence or absence of purified islet cells ( $5 \times 10^5$ /well) and cultured

at 37°C in 5% CO<sub>2</sub> for 24 h. Supernatants from cultures were collected for quantification of cytokines by Bio-Plex Pro Mouse Cytokine TH1/TH2 assay. Assays were conducted according to manufacturer's instructions and analyzed on a Bio-Plex 200 System (Bio-Rad; Hercules, CA).

**Statistics.** Results are expressed as mean±SEM, unless stated otherwise. Differences in gene expression were calculated using the nonparametric Mann-Whitney U tests. P<0.05 was considered as statistically significant. Statistical analysis was performed with the SPSS® Version 16.0 software package (SPSS Inc; Chicago, IL).

## RESULTS

*MLDS induces T cell mediated autoimmune diabetes.* To verify that MLDS is T cell dependent in our pathogen free colony (contrasting with previous work done in the 1980s in which experiments were not done in a specific pathogen free environment (25,31)) we injected WT, RAG1<sup>-/-</sup>, and nude B6 mice with MLDS. In all WT mice we detected progressively elevated serum glucose levels beginning on experimental day 7 and all became diabetic by experimental day 17. In contrast, we found that none of the RAG1<sup>-/-</sup> and none of the nude mice developed diabetes (Fig. 1A). In control experiments we observed that Hi-STZ (which directly destroys islet tissue) induced diabetes by experimental day 7 comparably in WT and RAG1<sup>-/-</sup> mice (Fig. 1A). On H&E stained pancreas tissues obtained on experimental day 19 we found significant intra- and peri-islet mononuclear infiltration in the pancreas of all WTs with a mean insulinitis score of 50.4±6.5% whereas we noted intact islets without any mononuclear cell infiltrates in all RAG1<sup>-/-</sup> mice (Fig. 1B).

To test whether the MLDS protocol induced islet-reactive T cell autoimmunity, we reasoned that following syngeneic islet transplantation, the primed islet-reactive,

cellular immune response would rapidly destroy the transplanted tissue and induce recurrent diabetes. To test this hypothesis, we isolated islets from WT B6 mice, pretreated them in vitro with STZ to facilitate neoantigen expression (29) and then transplanted 500 islets under the kidney capsules of syngeneic MLDS-induced diabetic B6 mice. We injected identically treated islets into Hi-STZ diabetic B6 recipient mice as controls. We observed that following transplantation, all animals rendered diabetic by either MLDS or Hi-STZ initially significantly lowered their serum glucose values by day 2 after transplantation, demonstrating that the transplanted islets were functional (Fig. 1C, D). Subsequently, the serum glucose of all of the transplanted MLDS-treated animals increased to pretransplant values within 1 week posttransplant (Fig. 1C). In contrast, in the Hi-STZ treated mice we found that islet transplantation markedly reduced and stabilized lower serum glucose in all animals and fully normalized serum glucose in 6 of 8 mice (Fig. 1D). On day 7 following transplantation, the MLDS recipients had a significantly impaired insulin response after i.p. glucose load compared to the Hi-STZ treated recipients (Fig. 1E). When we examined the pancreas tissue we found mononuclear cell infiltration in the transplanted islets from the MLDS treated mice but not in the Hi-STZ treated animals (Fig. 1F). Control experiments with islets that were not treated in vitro with STZ prior to transplantation into MLDS mice resulted in prolonged euglycemia (n=3) (data not shown). Together these experiments support the concept that MLDS induces autoimmune diabetes whereas Hi-STZ induces diabetes through an islet-toxic mechanism.

*C3 is required for MLDS-induced diabetes.* Because we (8,32,33), and others (34-36) showed that immune cell produced complement exerts control over T cell

autoimmunity in other models, we assessed the kinetics of complement component gene expression in total pancreatic tissue after MLDS administration using qRT-PCR. We detected gene transcripts for complement components C3 and factor B in pancreatic tissue obtained on experimental day 5 of MLDS. We noted that other complement components, receptors and regulators, including factor D, C3aR1, C5aR1 and decay accelerating factor (DAF) were detectable but were not increased during the same time period (Fig. 2). We did not detect C3 or factor B transcripts from purified islets obtained from untreated animals or from mice treated with MLDS on day 5 or day 10 (data not shown), suggesting that the pancreatic C3 derived from peri-islet immune cell infiltrates rather than from the islet cells.

To test whether C3 is required to induce diabetes following MLDS we administered MLDS to C3<sup>-/-</sup> mice on both C57BL/6 (n=12) and BALB/c (n=7) background. In contrast to the WT (C57BL/6 n= 11, BALB/c n=11) in which blood sugars exceeded 200 mg/dL at experimental day 11 in all mice, none of the C3<sup>-/-</sup> mice on either background developed hyperglycemia (Fig. 3A). While we found histological evidence of insulitis on experimental day 19 following MLDS in WT mice, we did not observe mononuclear infiltration within the islets of C3<sup>-/-</sup> animals (Fig. 3B). The mean insulitis score was 50.4±6.5% in WT vs. 5.3±2.7% in C3<sup>-/-</sup> mice (p<0.01) (Fig. 3B). In control experiments to test whether islets lacking C3 limits susceptibility to the effects of STZ, we co-cultured WT and C3<sup>-/-</sup> islets overnight with 0.5 mg/ml STZ. When we then tested the cultured islets for apoptosis, we found similar levels of Annexin V staining in WT islets and C3<sup>-/-</sup> islets, 50.1% vs. 56.3% respectively (Fig. S1). In confirmation of equivalent susceptibility to STZ, all Hi-STZ treated C3<sup>-/-</sup> mice (n=4) and WT mice (n=7) developed

diabetes with identical kinetics to the WT controls (Fig. 3A).

Because mononuclear cell chemoattractants CCL2 and CCL3 in addition to T cell derived IFN-γ and the innate cytokine IL-6 are implicated as mediators of insulitis, we measured their gene transcripts in pancreatic tissue of MLDS treated WT and C3<sup>-/-</sup> mice. Compared to WT mice, C3 deficiency was linked with lower expression of these genes, with CCL2 and CCL3 achieving statistical significance. Notably, we found that these differences were associated with lowered expression of the macrophage marker CD68 within the pancreas (Fig. 3C).

*Diminished T cell immunity to islet antigens in C3<sup>-/-</sup> mice.* To test the effect of C3 deficiency on the islet-reactive T cell response, we cultured spleen cells from MLDS-treated WT and C3<sup>-/-</sup> mice (and from untreated controls) in the presence or absence of purified islet cells and measured cytokine production in culture supernatants 24 h later (Fig. 4). These analyses revealed islet induced production of TNFα (experimental day 10) and IFN-γ (experimental day 19) in MLDS treated WT mice. Splenocytes obtained from untreated mice did not respond to islet stimulation, confirming that the noted cytokine production was induced by MLDS. In contrast to the results in WT mice, we did not detect cytokines in cultures of day 19 splenocytes obtained from MLDS treated C3<sup>-/-</sup> mice. Other cytokines including IL-17 and IL-10 were barely detectable and not different between groups (data not shown).

*MLDS-induced diabetes requires bone-marrow-cell-derived C3.* Because immune cell derived complement plays an integral role in adaptive T responses (13,37), we transplanted C3<sup>-/-</sup> (CD45.2) BM into lethally irradiated CD45.1 WT B6 mice (C3<sup>-/-</sup> BM→WT) to produce animals that contained serum C3 but possessed C3<sup>-/-</sup> BM cells. Conversely, we transplanted WT B6 CD45.1

BM into lethally irradiated CD45.2 C3<sup>-/-</sup> mice (WT BM→C3<sup>-/-</sup>) to produce animals deficient in serum C3 but with C3+ BM derived cells. WT BM→WT chimeras on the B6 background were produced as controls. Staining peripheral blood for CD45.1/CD45.2 and analyzing the cells by flow cytometry (Fig. 5A) verified that the immune cells were > 90% donor BM-derived. Zymosan C3 uptake assays (Fig. 5B) validated the presence or absence of C3 in the serum of each animal. We did not detect C3 in the sera of any WT BM→C3<sup>-/-</sup> chimeras (same as C3<sup>-/-</sup> controls) but we observed that all sera from C3<sup>-/-</sup> BM→WT and WT BM→WT chimeras was C3+ comparable to WT controls (Fig. 5B). When we administered MLDS to the chimeric animals, we found that only 2 of 8 C3<sup>-/-</sup> BM→WT chimeras developed diabetes, whereas all of the WT BM→C3<sup>-/-</sup> chimeras and all of the control WT BM→WT chimeras developed sustained hyperglycemia (Fig. 5C).

In separate “add back” experiments to test the requirement for spleen cell derived C3 in MLDS induced diabetes, we adoptively transferred 3x10<sup>6</sup> WT or control C3<sup>-/-</sup> spleen cells into C3<sup>-/-</sup> mice and then treated all animals with MLDS. While 2 of 3 C3<sup>-/-</sup> mice that received WT spleen cells became diabetic, none of four animals that received C3<sup>-/-</sup> spleen cells developed hyperglycemia (Fig. S2 in the online appendix available at <http://diabetes.diabetesjournals.org>).

## DISCUSSION

Taken together, our findings indicate that immune cell derived C3 is required for the development of diabetes in the MLDS model. We showed that in WT animals, MLDS-induced hyperglycemia and islet inflammation are associated with complement gene upregulation (Fig. 2). We then documented that C3 deficient mice, on 2 different genetic backgrounds, are resistant to MLDS induced diabetes (Fig. 3). This protective phenotype occurs in the absence of

islet inflammation (Fig. 3) and in association with diminished islet antigen-induced spleen cell-derived IFN-γ and TNFα production (Fig. 4). Using a bone marrow chimera strategy (and confirmed by spleen cell adoptive transfers), we showed that BM derived C3 and not serum C3 is critical for the development of autoimmune diabetes in this model (Fig. 5).

Previous mechanistic work performed by our group (5) demonstrated that cognate T cell/APC interactions result in release and activation of alternative pathway complement yielding locally produced C3a and C5a. These intermediaries bind to their respective receptors, C3aR and C5aR expressed directly on T cells, and through regulating AKT phosphorylation, augment T cell proliferation and prevent T cell apoptosis (5,11). The C3a and C5a also bind to their receptors on APCs, upregulating cytokine production and costimulatory molecule expression, which further amplify the T cell response (5). In the absence of C3 or in the absence of C3aR/C5aR, T cell proliferation is prevented, T cell apoptosis is enhanced, and APC produced cytokines and costimulatory molecule expression are reduced (5,11), together resulting in diminished cellular immune responses. Our new findings that islet-reactive T cell immunity and graft inflammation are diminished in MLDS treated C3<sup>-/-</sup> mice without diabetes are consistent with these mechanisms. In further support of role for these C3aR and C5aR signaling as an underlying mechanism for our observations, we found that only 1/5 mice deficient in both the C3aR and C5aR developed diabetes within 30 days after initiation of MLDS treatment (Fig. S3).

As others have demonstrated a key role for immune cell derived complement as an opsonin (38,39), limited antigen processing and presentation of autoantigens may contribute to the protective phenotype of the C3 deficient mice (40). Macrophage derived



C3, a key regulator of macrophage activation (41) may also be important in facilitating macrophage mediated islet injury (4,15). These, among other effects of C3 on regulating innate and adaptive immunity, require additional study.

It is notable that NOD mice develop spontaneous autoimmune diabetes despite being C5 deficient (42), indicating that C5, C5a, and the membrane attack complex (43) are not required in the pathogenesis of diabetes in that model system. Whether C3 and/or its activation cleavage products, C3a, C3b or C3dg are involved in the pathogenesis of diabetes in NOD mice is an issue that remains to be tested. However, the generation of C3<sup>-/-</sup> NOD mice is improbable due to the fact that both C3 and the diabetes susceptible H-2K<sup>d</sup> genes are located on chromosome 17 (17,18).

Our data support the interpretation that MLDS induced diabetes is in part an autoreactive, T cell mediated process. We showed that both T cell deficient nude mice and T and B cell deficient Rag1<sup>-/-</sup> mice do not develop hyperglycemia despite administration of MLDS that is pathogenic in WT animals (Fig. 1). Our documentation of recurrent

hyperglycemia following syngeneic islet transplantation of MLDS induced diabetic animals, but not diabetic mice induced by Hi-STZ (Fig. 1) supports this interpretation.

In summary, this work demonstrates an unanticipated key role for immune cell derived C3 in the pathogenesis of murine autoimmune diabetes. These results argue that studies testing the function of immune cell derived complement in human diabetes are warranted.

**Author Contributions.** M.L. researched data, wrote manuscript. N.Y. researched data. B.M. reviewed/edited manuscript. M.E.M. reviewed/edited manuscript. S.S. researched data. P.S.H. contributed to discussion, reviewed/edited manuscript. B.S. contributed to discussion, reviewed/edited manuscript.

## ACKNOWLEDGMENTS

The authors thank Dr. Jonathan Bromberg, Mount Sinai School of Medicine, for critical reading of the manuscript. The work was supported by NIH AI 071185 and JDRF grant 5-2008-954 awarded to PSH; KO8 AI 071038 to BS; NIH EY105476 and EY11288 to MEM.

## REFERENCES

1. Shizuru JA, Taylor-Edwards C, Banks BA, Gregory AK, Fathman CG. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. *Science* 1988;240:659-662
2. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. *Diabetes* 1993;42:44-55
3. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. *Biochem Pharmacol* 1998;55:1139-1149
4. Martin AP, Rankin S, Pitchford S, Charo IF, Furtado GC, Lira SA. Increased expression of CCL2 in insulin-producing cells of transgenic mice promotes mobilization of myeloid cells from the bone marrow, marked insulinitis, and diabetes. *Diabetes* 2008;57:3025-3033
5. Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, Shapiro VS, Dubyak GR, Heeger PS, Medof ME. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. *Immunity* 2008;28:425-435

6. Yalcindag A, He R, Laouini D, Alenius H, Carroll M, Oettgen HC, Geha RS. The complement component C3 plays a critical role in both Th1 and Th2 responses to antigen. *J Allergy Clin Immunol* 2006;117:1455-1461
7. Monach PA, Verschoor A, Jacobs JP, Carroll MC, Wagers AJ, Benoist C, Mathis D. Circulating C3 is necessary and sufficient for induction of autoantibody-mediated arthritis in a mouse model. *Arthritis Rheum* 2007;56:2968-2974
8. Liu J, Lin F, Strainic MG, An F, Miller RH, Altuntas CZ, Heeger PS, Tuohy VK, Medof ME. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. *J Immunol* 2008;180:5882-5889
9. Lalli PN, Zhou W, Sacks S, Medof ME, Heeger PS. Locally produced and activated complement as a mediator of alloreactive T cells. *Front Biosci (Schol Ed)* 2009;1:117-124
10. Pavlov V, Raedler H, Yuan S, Leisman S, Kwan WH, Lalli PN, Medof ME, Heeger PS. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection. *J Immunol* 2008;181:4580-4589
11. Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T cell expansion by limiting antigen-induced apoptosis. *Blood* 2008;112:1759-1766
12. Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N, Xu Y, Medof ME. Decay-accelerating factor modulates induction of T cell immunity. *J Exp Med* 2005;201:1523-1530
13. Verschoor A, Brockman MA, Gadjeva M, Knipe DM, Carroll MC. Myeloid C3 determines induction of humoral responses to peripheral herpes simplex virus infection. *J Immunol* 2003;171:5363-5371
14. Holers VM. The spectrum of complement alternative pathway-mediated diseases. *Immunol Rev* 2008;223:300-316
15. Hutchings P, Rosen H, O'Reilly L, Simpson E, Gordon S, Cooke A. Transfer of diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages. *Nature* 1990;348:639-642
16. Noorchashm H, Moore DJ, Lieu YK, Noorchashm N, Schlachterman A, Song HK, Barker CF, Naji A. Contribution of the innate immune system to autoimmune diabetes: a role for the CR1/CR2 complement receptors. *Cell Immunol* 1999;195:75-79
17. Circolo A, Garnier G, Fukuda W, Wang X, Hidvegi T, Szalai AJ, Briles DE, Volanakis JE, Wetsel RA, Colten HR. Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. *Immunopharmacology* 1999;42:135-149
18. Leiter EH, Lee CH. Mouse models and the genetics of diabetes: is there evidence for genetic overlap between type 1 and type 2 diabetes? *Diabetes* 2005;54 Suppl 2:S151-158
19. Wang Z, Gleichmann H. GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. *Diabetes* 1998;47:50-56
20. Brosky G, Logothetopoulos J. Streptozotocin diabetes in the mouse and guinea pig. *Diabetes* 1969;18:606-611
21. Liadis N, Murakami K, Eweida M, Elford AR, Sheu L, Gaisano HY, Hakem R, Ohashi PS, Woo M. Caspase-3-Dependent  $\beta$ -Cell Apoptosis in the Initiation of Autoimmune Diabetes Mellitus. *Mol. Cell. Biol.* 2005;25:3620-3629
22. Elias D, Prigozin H, Polak N, Rapoport M, Lohse AW, Cohen IR. Autoimmune diabetes induced by the beta-cell toxin STZ. Immunity to the 60-kDa heat shock protein and to insulin. *Diabetes* 1994;43:992-998

23. Kantwerk G, Cobbold S, Waldmann H, Kolb H. L3T4 and Lyt-2 T cells are both involved in the generation of low-dose streptozotocin-induced diabetes in mice. *Clin Exp Immunol* 1987;70:585-592
24. Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. *Diabetes* 1992;41:385-391
25. Nakamura M, Nagafuchi S, Yamaguchi K, Takaki R. The role of thymic immunity and insulinitis in the development of streptozotocin-induced diabetes in mice. *Diabetes* 1984;33:894-900
26. Paik SG, Fleischer N, Shin SI. Insulin-dependent diabetes mellitus induced by subdiabetogenic doses of streptozotocin: obligatory role of cell-mediated autoimmune processes. *Proc Natl Acad Sci U S A* 1980;77:6129-6133
27. Buschard K, Rygaard J. T-lymphocytes transfer streptozotocin induced diabetes mellitus in mice. *Acta Pathol Microbiol Scand [C]* 1978;86C:277-282
28. Schroppe B, Zhang N, Chen P, Zang W, Chen D, Hudkins KL, Kuziel WA, Sung R, Bromberg JS, Murphy B. Differential expression of chemokines and chemokine receptors in murine islet allografts: the role of CCR2 and CCR5 signaling pathways. *J Am Soc Nephrol* 2004;15:1853-1861
29. Weide LG, Lacy PE. Low-dose streptozotocin-induced autoimmune diabetes in islet transplantation model. *Diabetes* 1991;40:1157-1162
30. Reddy S, Karanam M, Krissansen G, Nitschke K, Neve J, Poole CA, Ross JM. Temporal relationship between immune cell influx and the expression of inducible nitric oxide synthase, interleukin-4 and interferon-gamma in pancreatic islets of NOD mice following adoptive transfer of diabetic spleen cells. *Histochem J* 2000;32:195-206
31. Sandler S, Andersson A. Survival of intrasplenically implanted islets in mice with experimental insulinitis and hyperglycemia. *Diabetes* 1982;31 Suppl 4:78-83
32. Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS. Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production. *J Immunol* 2007;179:5793-5802
33. Lin F, Spencer D, Hatala DA, Levine AD, Medof ME. Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. *J Immunol* 2004;172:3836-3841
34. Hietala MA, Jonsson IM, Tarkowski A, Kleinau S, Pekna M. Complement deficiency ameliorates collagen-induced arthritis in mice. *J Immunol* 2002;169:454-459
35. Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, Tretter T, Fairweather D, Holers VM, Rose NR. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. *Nat Immunol* 2001;2:739-745
36. Kuhn KA, Cozine CL, Tomooka B, Robinson WH, Holers VM. Complement receptor CR2/CR1 deficiency protects mice from collagen-induced arthritis and associates with reduced autoantibodies to type II collagen and citrullinated antigens. *Mol Immunol* 2008;45:2808-2819
37. Kemper C, Atkinson JP. T-cell regulation: with complements from innate immunity. *Nat Rev Immunol* 2007;7:9-18
38. Premanandan C, Storozuk CA, Clay CD, Lairmore MD, Schlesinger LS, Phipps AJ. Complement protein C3 binding to *Bacillus anthracis* spores enhances phagocytosis by human macrophages. *Microb Pathog* 2009;46:306-314
39. Walport MJ. Complement. First of two parts. *N Engl J Med* 2001;344:1058-1066

40. Li K, Anderson KJ, Peng Q, Noble A, Lu B, Kelly AP, Wang N, Sacks SH, Zhou W. Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. *Blood* 2008;112:5084-5094
41. Zhou W, Patel H, Li K, Peng Q, Villiers MB, Sacks SH. Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. *Blood* 2006;107:2461-2469
42. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. *J Immunol* 1995;154:180-191
43. Baxter AG, Cooke A. Complement lytic activity has no role in the pathogenesis of autoimmune diabetes in NOD mice. *Diabetes* 1993;42:1574-1578

## Figure Legends

### Figure 1. MLDS-induced diabetes is T cell dependent.

(A) Cumulative diabetes incidence and mean blood glucose levels in MLDS WT (n=11), MLDS Rag1<sup>-/-</sup> (n=7), MLDS nude (n=5), Hi-STZ WT (n=7), and Hi-STZ Rag1<sup>-/-</sup> (n=4) mice. (B) Histopathology of pancreatic sections from WT and Rag1<sup>-/-</sup> mice stained with H&E from experimental day 19 MLDS mice reveal infiltration present in WT but absent in Rag1<sup>-/-</sup> mice. Arrowhead indicates areas of infiltration; original magnification x200. 500 islets were pretreated with 0.5 mg/ml STZ for 1 hour then transplanted into (C) MLDS (n=7) and (D) Hi-STZ (n=8) treated syngeneic recipients. Individual blood glucose levels are shown. (E) Histopathology of transplanted islets from MLDS and Hi-STZ treated mice stained with H&E day 15 after transplantation. Heavy infiltration (arrowhead) was present in the transplanted islets from MLDS but not Hi-STZ mice; original magnification x200. (F) AUC was calculated from glucose tolerance test performed on day 7 after islet transplantation in addition to control nondiabetic mice (n=6).

### Figure 2. MLDS induces the differential expression of complement genes.

Total pancreata were isolated from MLDS treated WT mice on experimental day 0, 5, and 10 and complement genes were analyzed by qRT-PCR (n=6 per time point). C3 and factor B mRNA expression levels (normalized to cyclophilin) increased significantly after MLDS while factor D, C3aR1, and C5aR1 remained unchanged. DAF expression showed increasing trend. Box and whisker blots show the medians, and the percentile values (10, 25, 75, 90) for normalized mRNA.

### Figure 3. C3 deficiency protects from MLDS-induced diabetes.

(A) Cumulative diabetes incidence and average blood glucose levels of WT or C3<sup>-/-</sup> mice on both the B6 and Balb/c background after administration of MLDS (n=7-11 per group) or Hi-STZ (n=3-4); \*\*p<0.01 (comparing blood glucose level of WT vs C3<sup>-/-</sup> on day 17). (B) Histopathology of pancreata on experimental day 19 of MLDS showing mononuclear cell infiltration in WT but not in C3<sup>-/-</sup> mice. Arrowheads indicate areas of infiltration; original magnification x200. Mean insulinitis scores (%±SEM) of mice on experimental day 19 were obtained from three mice for each group. p<0.01 (C) qRT-PCR of CCL2, CCL3, IFN-γ, IL-6, and macrophages (CD68) from total pancreata (normalized to cyclophilin) on experimental day 0, 5, and 10 after initiation of MLDS (n=6 per group and time point) with C3<sup>-/-</sup> mice with lower expression compared to WT mice. Box and whisker blots show the medians, and the percentile values (10, 25, 75, 90) for normalized mRNA.

### Figure 4. Presence of C3 is required in T cell priming and activation.

Cytokines produced by splenocytes isolated from MLDS treated mice and then stimulated with islet cells for 24 hours. C3<sup>-/-</sup> cells had significantly lower production of TNFα (experimental day 10) and IFN-γ (experimental day 19) compared to WT. Supernatants were analyzed in duplicates by Luminex and the data shown are representative of three independent experiments.

### Figure 5. Functional C3 on BM derived cells and not systemic C3 is required for development of MLDS-diabetes.

(A)  $C3^{-/-}$  BM→WT (n=8), WT BM→ $C3^{-/-}$  (n=6), and WT BM→WT (n=6) chimeric mice were stained for CD45.2 and CD45.1 and analyzed by flow cytometry to verify lethal irradiation and bone marrow engraftment on week 8. (B) Zymosan C3 binding assay confirming presence of systemic C3 in WT and absence in  $C3^{-/-}$  mice. (C) Cumulative diabetes incidence and average blood glucose levels after administration of MLDS in chimeric mice. Results represent two independent experiments.

Figure 1




Figure 2




Figure 3




Figure 4






Figure 5

